Because of insufficient number of umbilical cord blood hematopoietic stem cells (UCB-HSCs), expansion of these cells seems to be important for clinical application in adults. The aim of this study was to co-culture of UCB-HSCs with the amniotic membrane derived mesenchymal stem cells (AMMSCs) as a feeder layer in order to expand hematopoietic stem cells (HSCs). UCBs and amniotic membrane were collected from concern mothers. Ex vivo culture of UCB-HSCs were performed in four culture conditions: cytokine cocktail with MSCs feeder layer, cytokine cocktail, stem cell factor, and co-culture with MSCs without any cytokine. The number of total nucleated cells (TNC) was counted by hemocytometer. The HSC count and immunophenotyping of Mesenchymal stem cells (MSCs) and expanded HSC were evaluated by flow cytometry. Colony forming unit (CFU) assay was used to evaluate the potential of expanded HSCs for production of different lineage colonies. The mean fold changes of total nucleated cells (TNC) and CD34+ cells in the cytokine culture with feeder layer were higher than the cytokine culture without MSCs. However, in the co-culture system without cytokine, TNC and CD34+ cell numbers were increased up to 8 folds, but cell viability was more than 80% and differentiation rate was low. Our results demonstrated that we could increase the number of CD34+ cells of UCB that were used as primary HSC for transplantation.
Hematopoietic stem cells (HSCs) have been known as primitive, undifferentiated cells that have self-renewability and differentiation into all blood cell types 1, 2 . Their progeny, referred to hematopoietic progenitor cells (HPC), contain cells with a limited capacity to self-renew 3, 4 . The functioning of hematopoietic stem cells (HSCs) related to internal regulators 1, 5 , which are adjusted by external signals such as cytokines and extracellular matrix produced by stromal and auxiliary cells. Together, stromal and auxiliary cells and their products organize a complex structural and functional network known as the hematopoietic microenvironment (HM) 6, 7 . During the last two decades, another source for HSCs, except bone marrow, was described such as peripheral blood cells and umbilical cord blood (UCB). HSCs have become a central issue in the study of hematopoiesis, playing a key role in the development of novel strategies for HSC transplantation and have become an important source of HSCs for myeloablative and nonmyeloablative therapies 7 .
Clinical trials have basically shown that UCB transplantation causes less graft versus host disease (GVHD) and graft failure (8) . Recipients seem to be less sensitive to HLA mismatching when UCB is used as a source of HSCs/HPCs. One clinically interesting fact is that UCB myeloid progenitor cells are relatively chemo-resistant (9) . The major limiting factor to UCB usage is the low cell dose available for transplantation. It is shown that the total nucleated cell (TNC) dose transplanted per kg of body weight of the recipient correlates with results. Patients with a total body weight of at least 45 kg who receive only a single unit of UCB have been shown to have a significant delay in time to neutrophil and platelet engraftment, as well as higher risk of engraftment failure 1, 5, 6, 10, 11 . For this reason different experimental systems was designed for expansion HSC and two major aims are followed in the near future: first, the generation of HSCs that retain multipotentiality and selfrenewal and the second is, production of such cells in sufficient numbers for their clinical usage 12 . Currently, several ways exist for ex vivo HPCs expansion. A combination of several cytokines is typically used for ex vivo culture of HSCs/HPCs. Although there are not the exact combination of cytokines, but it usually consists of several cytokines such as Flt3/Flk2 ligand 6, 13 , interleukin-3 (IL-3) 14, 15 , IL-6 6, 16 , and thrombopoietin 6, [17] [18] [19] . Primary clinical trials using CD34+ or CD133+ selected UCB cells expanded in an ex-vivo expansion system have used for transplantation 20 . This stimulated our interest in strategies that might improve the expansion capability of HSCs that generated with co-cultures system. The majority of static liquid culture ex vivo expansion systems first require the isolation of CD34+ or CD133+ HPCs from fresh or frozen hematopoietic tissue 21, 22 . Clinically, liquid ex vivo expansion of CD34+ UCB cells was reported to increase TNC by 56-fold and the total number of CD34+ cells by 4 fold 23 . One kind of cells that exists in microenvironment of HSCs is mesenchymal stem cell (MSCs). MSCs have some sources such as BM, adipose tissue, placenta and amniotic membrane.
Objectives
In current research we use amniotic derived MSCs (AMMSCs) for the first time as microenvironment for co-culture HSCs. In our current UCB expansion protocols, CD34+ cells are isolated before culture. Thus, we thought to develop a UCB expansion method, which would increase the expanded cell dose available for transplantation.
MATERIALS AND METHODS

Isolation of HSCs
HSCs were collected from fresh human UCB. The blood were taken from normal full-term pregnant women after written informed consent and according to guidelines approved by the Ethics Committee at the Iranian Blood Transfusion Organization. Mononuclear cells (MNCs) were isolated by density gradient centrifugation on Ficoll-Hypaque (Bio sciences, Sweden). The MNCs were incubated with anti-human CD34+ conjugated with MicroBeads, (Miltenyi Biotec, USA) for 30 min at 4 °C. CD34+ cells were isolated using an affinity column.
Isolation and Cultivation of AMMSCs
The human amnion was mechanically peeled from the chorion of a placenta obtained from an un-complicated cesarean section with informed consent. AMMSCs were isolated by sequential trypsin and collagenase digestion as described previously 24 . Briefly, the amnion was washed in phosphate-buffered saline (PBS) and then cut into the pieces. The resulting minced amnion was digested with 0.2% trypsin (Sigma-Aldrich, Germany) and collagenase in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma, UK). After incubation at 37°C with stirring at 100 rpm for 30 min, the medium was removed. The tissue was minced again and incubated at 37°C in DMEM with trypsin and stirred at 400-600 rpm for 30 min. The mixture was then poured over gauze to separate the dispersed amnion cells from the tissue pieces. The dispersed cells were collected by centrifugation and suspended in DMEM supplemented with heat-inactivated 10% FCS (Gibco, USA) and 1% antibioticantifungal solution (Gibco, USA) and then seeded into culture dishes (Greiner Bio-One, Germany) at a concentration of 3.0 × 10 4 cells / cm 2 . Incubation was carried out at 37°C under 5% CO2 in air. The MSCs were characterized by flow cytometric analysis using monoclonal antibodies against CD105, CD44, CD166, CD29,CD73 and CD34,CD45 (Dako, Denmark). Differentiation potential of MSCs was investigated by osteogenic differentiation and adipogenic differentiation.
Ex vivo Expansion of CD34+ Enriched Cells
CD34+ enriched cells were cultured in 4 well plates (Nunc, Denmark) for 10 days in the serum-free medium (Stem cell technology, Denmark) at 37 °C under 5% CO 2 
RESULTS
AMMSCs Characterization and Immunophenotyping
MSCs were positive for the following adhesion molecules: CD44, CD166, CD73, CD105, and CD29 which were considered as markers for MSCs. As shown, the MSCs were negative for hematopoietic lineage markers, namely, CD34, and CD45 (Figure 1 ).
Osteogenic and Adipose Differentiation Assay
Osteogenic differentiation potential of AMMSCs was assayed by alizarian red staining and evaluation of alkaline phosphatase activity. Also, 
Ex vivo Expansion of CD34+ Enriched Cells
Purity of separated CD34+ cells, determined by flow cytometric analysis, was 92.69 ± 14.00 %. Moreover, 6.81 ± 7.00% of them were positive for the CD38 marker (n=3) (figures 4). Ex vivo expansion of human cord blood CD34+ enriched cells in serum-free medium supplemented with SCF, TPO and FLT3L was evaluated either with or without feeder layer using flow cytometric analysis (Figure 4) . Figures 3 show the fold increase in TNC and number of CD34+ cells during 10-day liquid cytokine culture in the presence and absence of human MSCs and in the co-culture system without cytokine. Increase in culture with only SCF is lower than the other conditions. Maximum expansion was observed at 7 th day of culture in all the four culture conditions. In the co-culture system without cytokine, the mean fold change of TNC was 8.40 ± 2.30, in cytokine culture without MSCs feeder layer was 20.00 ± 8.96, in the co-culture system with cytokines was 25.50 and in the culture with SCF was 6 at 7 th of culture. The mean fold change of CD34+cells was 20.10 ± 2.30 in cytokines supplemented culture and 25.56 ± 24.83 in the co-culture system with cytokines. In the co-culture without cytokine the fold increase in CD34+ was 8.43 and in the culture with SCF was 4.84 (n = 6) (Figure 3a) . Expansion of CD34þ+ selected UCB cells at 10 th day of both cytokine culture and co-culture with cytokines was decreased, and relative differentiation was also observed. So the mean fold change of TNC and CD34+ cells at 7 th day in the co-culture system with cytokines was higher than the cytokine culture without MSCs feeder layer and co-culture system without cytokines significantly (n = 6, P < 0.05). However, in the co-culture system without cytokine TNC and CD34+ cell numbers were increased up to 8 folds, the cell viability was remained 80% after 10 days (Figure 3 a and b) .
Colony Forming Cell Assays
The highest CFU fold change was also observed in cytokine culture with MSCs at 10 th day (125 ± 24) ( Figure 6 ). The CFU increase in cytokine culture without MSCs at 10 th day was 91 ± 13, in co-culture with MSC was 52 ± 9 and in the culture without cytokine was 39. hence the mean fold change of CFU at 10 th day in both cytokine cultures with and without MSCs feeder layer was higher than co-culture system without cytokines significantly (n = 3, P < 0.05), but there was no significant differences between two cytokine cultures with and without MSCs feeder layer (Figure 4) .
DISCUSSION
This study compared the supporting effects of AMMSCs alone or in combination with cytokines in the proliferation and differentiation of HSCs. Ex vivo expansion of UCB-HSCs at different conditions of culture recombinant stimulatory cytokines is one way to increase the number of CD34+ cells and UCB-HSCs 25 . The number of CD34+ cells of UCB that were used as primary HSCs for transplantation can increase significantly 26 . Data presented here demonstrate that the ex vivo co-culture CD34+ cells with MSCs generated superior TNC and HPC expansion. The improved TNC and HPC expansion observed during the CD34+ MSC co-culture would be consistent with the observation that ex vivo contact with stromal components of the HM preserves HSCs activity 27, 28 . Moreover, in this study, UCB-CD34+ cells expansion with hematopoietic cytokines in the absence or presence of human AMMSCs feeder layer and in co-culture and culture system without cytokine was performed. The mean fold changes of TNC and CD34+ cells in the cytokine culture with MSCs were higher than the cytokine culture without MSCs. However, in the co-culture system without cytokine TNC and CD34+ cell numbers were increased up to 8 folds, but cell viability was more than 80% and differentiation rate was low 29 . In the present study, maximum expansion was observed at 7 th day of culture in the two cytokine supplemented cultures. Moreno et al (2010) reported that UCB derived CD34+ cells showed significant proliferation after 14 days in the cytokine culture and maximum expansion was observed at 7 th day of culture 30 . Also, Walenda et al (2010) showed that MSCs and cytokines have synergistic effect on HSCs expansion 31 . Robinson et al (2006) reported that MSCs co-culture with UCB cells without the need for an initial positive selection step (and the associated loss of HPC) might produce a UCB graft with better engraftment potential 32 . Our mean fold change of UCB-CD34+ with cytokines and without feeder layer was 20.1 that is similar to results of Mohamed (2006 34 . In agreement with our results, Jang et al showed that proliferation capacity of HSCs in the recombinant cytokine culture with UCB-MSCs feeder layer was higher than the cytokine culture without MSCs, and in the co-culture system without cytokine CD34+ cell numbers were increased up to 8 folds 35 . Also, Silvaa et al (2005) cultured UCB-CD34+enriched cells in serum-free medium supplemented with SCF, LIF, and FLT-3, in the presence or absence of stroma, and observed that the stromal layers would support process of expansion without the exhaustion of the more primitive stem cells and differentiation induction (36) . However, present study suggests that MSC co-culture of a UCB unit will yield approximately 5 × 106 TNC (and approximately 4.7 × 106 CD34+ cells). This yield would be sufficient to provide a transplant dose for a > 75 kg recipient. This procedure would therefore potentially permit the transplantation of patients > 75 kg who are currently precluded from receiving UCB units because single UCB units with acceptable cell doses are not available. On the other hand, comparison of the results of the present study with others showed that the percentage of CD34+ was higher than the others up to 90% that maybe related to the different source for feeder of culture. Based on our results, use of amniotic membrane for extraction of MSCs is suggested.
In conclusion expression of CD34+ cells in HSCs were increased during ex vivo expansion. Also, among several studies investigating different types of feeder layer-based culture systems, amniotic derived MSCs are more effective than stroma-free culture system (supplemented with cytokines). Previous studies showed that CD34+ cells derived from cord blood are capable of functional hemato-endothelial development. However, the relationship between CD34+ and embryonic stem cell-derived MSC remains unknown. Future studies must be focused on the developmental hierarchy of CD34+ and MSCs, the functional engraftment of present CD34+ cells and AMMSCs progenitor cells and the potential clinical application for adult and children disorders.
